NASDAQ:OREX - Orexigen Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $0.2229 0.00 (0.00 %) (As of 07/23/2018 09:45 AM ET)Previous Close$0.2229Today's RangeN/A52-Week Range$0.17 - $3.81VolumeN/AAverage Volume1.16 million shsMarket Capitalization$4.21 millionP/E Ratio-0.03Dividend YieldN/ABeta2.46 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Receive OREX News and Ratings via Email Sign-up to receive the latest news and ratings for OREX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:OREX CUSIP68616410 Webwww.orexigen.com Phone858-875-8600 Debt Debt-to-Equity Ratio-2.75 Current Ratio2.00 Quick Ratio1.71 Price-To-Earnings Trailing P/E Ratio-0.03 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$33.71 million Price / Sales0.12 Cash FlowN/A Price / CashN/A Book Value$3.91 per share Price / Book0.06 Profitability EPS (Most Recent Fiscal Year)($6.92) Net Income$-24,520,000.00 Net Margins-192.65% Return on EquityN/A Return on Assets-68.53% Miscellaneous Employees132 Outstanding Shares18,890,000Market Cap$4.21 Orexigen Therapeutics (NASDAQ:OREX) Frequently Asked Questions What is Orexigen Therapeutics' stock symbol? Orexigen Therapeutics trades on the NASDAQ under the ticker symbol "OREX." How were Orexigen Therapeutics' earnings last quarter? Orexigen Therapeutics, Inc. (NASDAQ:OREX) posted its quarterly earnings results on Monday, November, 13th. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, topping the consensus estimate of ($2.13) by $0.78. The biopharmaceutical company earned $18.90 million during the quarter, compared to the consensus estimate of $24.20 million. The business's revenue for the quarter was up 170.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.12 earnings per share. View Orexigen Therapeutics' Earnings History. What is the consensus analysts' recommendation for Orexigen Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orexigen Therapeutics in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." Who are some of Orexigen Therapeutics' key competitors? Some companies that are related to Orexigen Therapeutics include Agile Therapeutics (AGRX), Relmada Therapeutics (RLMD), IntelliPharmaCeutics Intl (IPCI), Flex Pharma (FLKS), Sonoma Pharmaceuticals (SNOA), Pain Therapeutics (PTIE), Wellness Center USA (WCUI), DelMar Pharmaceuticals (DMPI), Dare Bioscience (DARE), Cellectar Biosciences (CLRB), THERAPIX BIOSCI/S (TRPX), Endonovo Therapeutics (ENDV), OHR Pharmaceutical (OHRP), Ritter Pharmaceuticals (RTTR) and Soligenix, Inc. Common Stock (SNGX). Who are Orexigen Therapeutics' key executives? Orexigen Therapeutics' management team includes the folowing people: Mr. Michael A. Narachi, Pres, Chief Exec. Officer & Director (Age 59)Dr. Thomas R. Cannell D.V.M., Exec. VP, COO & Pres of Global Commercial Products (Age 56)Mr. Thomas P. Lynch, Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. (Age 51)Ms. Monica Forbes, VP & Acting CFO (Age 42)Mr. Stephen A. Moglia, Chief Accounting Officer, VP and Controller (Age 53) Has Orexigen Therapeutics been receiving favorable news coverage? Media headlines about OREX stock have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Orexigen Therapeutics earned a daily sentiment score of 0.22 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.22 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days. How do I buy shares of Orexigen Therapeutics? Shares of OREX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Orexigen Therapeutics' stock price today? One share of OREX stock can currently be purchased for approximately $0.2229. How big of a company is Orexigen Therapeutics? Orexigen Therapeutics has a market capitalization of $4.21 million and generates $33.71 million in revenue each year. The biopharmaceutical company earns $-24,520,000.00 in net income (profit) each year or ($6.92) on an earnings per share basis. Orexigen Therapeutics employs 132 workers across the globe. How can I contact Orexigen Therapeutics? Orexigen Therapeutics' mailing address is 3344 N. TORREY PINES CT. SUITE 200, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-875-8600 or via email at [email protected] MarketBeat Community Rating for Orexigen Therapeutics (NASDAQ OREX)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 208 (Vote Outperform)Underperform Votes: 221 (Vote Underperform)Total Votes: 429MarketBeat's community ratings are surveys of what our community members think about Orexigen Therapeutics and other stocks. Vote "Outperform" if you believe OREX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OREX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/23/2018 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?